609 results match your criteria: "Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases[Affiliation]"

Objectives: Late-onset epilepsy has the highest incidence among all age groups affected by epilepsy and often occurs in the absence of known clinical risk factors such as stroke and dementia. There is increasing evidence that brain changes contributing to epileptogenesis likely start years before disease onset, and we aim to relate cognitive and imaging correlates of subclinical brain injury to incident late-onset epilepsy in a large, community-based cohort.

Methods: We studied Offspring Cohort of the Framingham Heart Study participants 45 years or older, who were free of prevalent stroke, dementia, or epilepsy, and had neuropsychological (NP) evaluation and brain magnetic resonance imaging (MRI).

View Article and Find Full Text PDF

Background: Optical coherence tomography (OCT) enables high-resolution imaging of ocular structures in health and disease. Choroid thickness (CT) is a key vascular retinal parameter that can be assessed by OCT and might be relevant in the evaluation of the vascular component of cognitive decline. We aimed to investigate CT changes in a large cohort of individuals cognitive unimpaired (CU), with mild cognitive impairment due to Alzheimer's (MCI-AD), mild cognitive impairment due to cerebrovascular disease (MCI-Va), Alzheimer's disease dementia (ADD), and vascular dementia (VaD).

View Article and Find Full Text PDF
Article Synopsis
  • A genome-wide association study was conducted to analyze cerebrospinal fluid (CSF) and brain metabolite levels, revealing 205 associations for CSF metabolites and 32 for brain metabolites, with a significant portion being new signals.
  • The research found that most new signals for CSF (96.9%) and brain metabolites (71.4%) were related to previously studied metabolites in blood and urine.
  • The study identified 71 metabolite-trait associations linked to various neurological and psychiatric conditions, enhancing understanding of how brain metabolism may influence human traits and diseases.
View Article and Find Full Text PDF

The integration of quantitative trait loci (QTLs) with disease genome-wide association studies (GWASs) has proven successful in prioritizing candidate genes at disease-associated loci. QTL mapping has been focused on multi-tissue expression QTLs or plasma protein QTLs (pQTLs). We generated a cerebrospinal fluid (CSF) pQTL atlas by measuring 6,361 proteins in 3,506 samples.

View Article and Find Full Text PDF
Article Synopsis
  • Short sleep duration is linked to cognitive impairment and dementia, particularly worsened by hypertension.
  • A study involving 682 participants found that those with hypertension showed a decline in executive functioning and an increase in brain injury with shorter sleep.
  • The relationship between sleep and cognitive performance was not observed in participants without hypertension, highlighting the importance of managing sleep and blood pressure for brain health.
View Article and Find Full Text PDF

Association of Self-Reported Sleep Characteristics With Neuroimaging Markers of Brain Aging Years Later in Middle-Aged Adults.

Neurology

November 2024

From the Departments of Psychiatry and Behavioral Sciences (C.C., C.D., Y.L., K.Y.), Neurology (K.Y.), and Epidemiology (K.Y.), University of California, San Francisco; Neuroimage Analytics Laboratory and Biggs Institute Neuroimaging Core (M.H.), Glenn Biggs Institute for Neurodegenerative Disorders, University of Texas Health Science Center at San Antonio; Center for AI and Data Science for Integrated Diagnostics and Center for Biomedical Image Computing and Analytics (M.H.), University of Pennsylvania, Philadelphia; and Department of Preventive Medicine (M.R.C.), Northwestern University Feinberg School of Medicine, Chicago, IL.

Article Synopsis
  • The study aimed to explore how sleep patterns in early midlife affect brain aging in late midlife using data from the CARDIA study.
  • Researchers analyzed sleep data, focusing on factors like sleep duration and quality, and later assessed brain age through MRIs taken 15 years later.
  • Results showed that individuals with more poor sleep characteristics had significantly older brain ages, emphasizing the need for sleep interventions to support brain health.*
View Article and Find Full Text PDF

Relationship between MRI brain-age heterogeneity, cognition, genetics and Alzheimer's disease neuropathology.

EBioMedicine

November 2024

AI(2)D, Center for AI and Data Science for Integrated Diagnostics, and Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA. Electronic address:

Background: Brain ageing is highly heterogeneous, as it is driven by a variety of normal and neuropathological processes. These processes may differentially affect structural and functional brain ageing across individuals, with more pronounced ageing (older brain age) during midlife being indicative of later development of dementia. Here, we examined whether brain-ageing heterogeneity in unimpaired older adults related to neurodegeneration, different cognitive trajectories, genetic and amyloid-beta (Aβ) profiles, and to predicted progression to Alzheimer's disease (AD).

View Article and Find Full Text PDF
Article Synopsis
  • Subcortical brain structures play a crucial role in various developmental and psychiatric disorders, and a study analyzed brain volumes in 74,898 individuals, identifying 254 genetic loci linked to these volumes, which accounted for up to 35% of variation.
  • The research included exploring gene expression in specific neural cell types, focusing on genes involved in intracellular signaling and processes related to brain aging.
  • The findings suggest that certain genetic variants not only influence brain volume but also have potential causal links to conditions like Parkinson’s disease and ADHD, highlighting the genetic basis for risks associated with neuropsychiatric disorders.
View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease (AD) is a common hereditary disorder affecting the elderly, and this study explored its genetic associations using whole genome sequencing data from 13,371 individuals of various ancestries.
  • The researchers found significant genetic variants related to AD, including those at APOE, BIN1, and a specific haplotype on chromosome 14 (PSEN1) in Hispanic populations, alongside variants in LINC00320 in Black individuals.
  • The study highlights the importance of both pooled and subgroup-specific analyses in understanding the complex genetic architecture of AD, revealing rare non-coding variants in the promoter of TOMM40 unrelated to APOE.
View Article and Find Full Text PDF

Human microglia play a pivotal role in neurological diseases, but we still have an incomplete understanding of microglial heterogeneity, which limits the development of targeted therapies directly modulating their state or function. Here, we use single-cell RNA sequencing to profile 215,680 live human microglia from 74 donors across diverse neurological diseases and CNS regions. We observe a central divide between oxidative and heterocyclic metabolism and identify microglial subsets associated with antigen presentation, motility and proliferation.

View Article and Find Full Text PDF

Involvement of Renin-Angiotensin system (RAS) components in mild traumatic brain injury.

Brain Res

January 2025

Department of Morphology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address:

Article Synopsis
  • The study examines how the Renin Angiotensin System (RAS) is involved in mild traumatic brain injury (mTBI), focusing on changes in RAS components in an animal model.
  • It found increased levels of certain RAS components in specific brain regions after injury, alongside changes in receptor expression over time.
  • Treatment with RAS-blocking medications improved motor activity and reduced anxiety in mTBI mice, suggesting potential therapeutic options for managing mTBI symptoms.
View Article and Find Full Text PDF
Article Synopsis
  • Subcortical brain structures play a crucial role in various disorders, and a study analyzed the genetic basis of brain volumes in nearly 75,000 individuals of European ancestry, revealing 254 loci linked to these volumes.
  • The research identified significant gene expression in neural cells, relating to brain aging and signaling, and found that polygenic scores could predict brain volumes across different ancestries.
  • The study highlights genetic connections between brain volumes and conditions like Parkinson's disease and ADHD, suggesting specific gene expression patterns could be involved in neuropsychiatric disorders.
View Article and Find Full Text PDF

Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimer's disease continuum.

Transl Psychiatry

October 2024

Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI2D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Article Synopsis
  • Alzheimer's disease (AD) exhibits varied brain atrophy patterns, identified through a semi-supervised learning technique (Surreal-GAN) that distinguishes between "diffuse-AD" (widespread atrophy) and "MTL-AD" (focal atrophy in the medial temporal lobe) dimensions in patients with mild cognitive impairment (MCI) and AD.
  • Only the "MTL-AD" dimension was linked to known AD genetic risk factors like APOE ε4, and both dimensions were later detected in asymptomatic individuals, revealing their association with different genetic and pathological mechanisms.
  • Aside from brain-related genes, up to 77 additional genes were identified in various organs, pointing to broader
View Article and Find Full Text PDF

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.

J Prev Alzheimers Dis

October 2024

Prof. Frank Jessen, MD, Department of Psychiatry, University of Cologne, Kerpener Strasse 62, 50937 Cologne, Germany, Tel.: +49-(0)221 478-4010

β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer's disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer's Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now.

View Article and Find Full Text PDF

Can Pharmaceutical Care Interventions Improve the Appropriate Use of Polypharmacy in Older Adults?-A Cochrane Review Summary With Commentary.

Am J Phys Med Rehabil

December 2024

From the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, Texas, and Graduate School of Biomedical Sciences, University of Texas Health Science Center, San Antonio, Texas.

View Article and Find Full Text PDF

Gene-Specific Effects on Brain Volume and Cognition of in Frontotemporal Lobar Degeneration.

Neurology

October 2024

From the VIB Center for Molecular Neurology (M.V., R.R., V.B., S.W.); Department of Biomedical Sciences (M.V., M.V.B., S.W., R.R.), University of Antwerp, Belgium; Department of Neurology (E.M.R., M.F.M.), David Geffen School of Medicine, University of California, Los Angeles; Department of Neurology (N.C.-L., V.K.R., T.K., K.K., B.F.B.); Department of Psychiatry and Psychology (N.C.-L., J.A.F., D.S.K., L.K.F.), Mayo Clinic, Rochester, MN; Department of Epidemiology and Biostatistics (J.K.), University of California, San Francisco; Department of Quantitative Health Sciences (C.M., D.E.B.), Mayo Clinic, Rochester, MN; Department of Neurology (A.M.S., A.A.W.), Memory and Aging Center, University of California, San Francisco; Weill Institute for Neurosciences, San Francisco, California; Institute for Precision Health (D.H.G.), Departments of Neurology, Psychiatry and Human Genetics at David Geffen School of Medicine, UCLA; Department of Neuroscience (T.G., L.P., M.B., N.R.G.-R.), Mayo Clinic, Jacksonville, FL; Alzheimer's Disease and Other Cognitive Disorders Unit (S.B.-É.), Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Fundació Clínic per a la Recerca Biomèdica, Uni; Department of Neurology (B.A., B.C.D.), Case Western Reserve University, Cleveland, OH; Department of Neurology (S.B.), University of Michigan, Ann Arbor; Department of Neurology (A.C.B.), University of North Carolina, Chapel Hill; Department of Neurology (D.C.), Indiana University, Indianapolis; Department of Neurology (R.R.D.), Vanderbilt University, Nashville, TN; Department of Neurology (K.D.-R.), University of Washington, Seattle, WA; Department of Neurosciences (D.G., G.C.L., I.L.), University of California, San Diego, La Jolla; Departments of Neurology and Psychiatry (N.G.), Washington University School of Medicine, Washington University, St. Louis, MO; Department of Psychiatry and Behavioral Sciences (I.M.G.), Northwestern Feinberg School of Medicine, Chicago, IL; Taub Institute for Research on Alzheimer's Disease and the Aging Brain (L.S.H.), College of Physicians and Surgeons; Department of Neurology (L.S.H.), Columbia University, New York; Division of Neurology (G.-Y.R.H.), University of British Columbia, Vancouver, Canada; Department of Psychiatry and Human Behavior (E.D.H.), Alpert Medical School of Brown University, Providence, RI; Department of Neurology and Penn Frontotemporal Degeneration Center (D.J.I.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; National Institute of Neurological Disorders and Stroke (J.Y.K., A.S.), National Institutes of Health, Bethesda, MD; Department of Neurology (J.C.M., B.P.), Houston Methodist, TX; Department of Psychiatry and Behavioral Sciences (C.U.O.), Johns Hopkins University, Baltimore, MD; Department of Neurology (P.S.P.), University of Colorado, Aurora; Cleveland Clinic Lou Ruvo Center for Brain Health (A.R., D.W.), Las Vegas, NV; Department of Neurology (E.D.R.), University of Alabama at Birmingham; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases (A.C.S.), UT Health San Antonio; Tanz Centre for Research in Neurodegenerative Diseases (M.C.T.), Division of Neurology, University of Toronto, Ontario, Canada; Department of Neurology (H.W.H., A.L.B., H.J.R.), Memory and Aging Center, University of California, San Francisco; Weill Institute for Neurosciences, San Francisco, CA; and Department of Neuroscience (R.R.), Mayo Clinic, Jacksonville, FL.

Article Synopsis
  • The study investigates the role of the genetic variant rs1990622 as a potential modifier of disease risk in frontotemporal lobar degeneration (FTLD), particularly among those with pathogenic variants.
  • Researchers enrolled participants from the ALLFTD study, analyzing the impact of rs1990622 on gray matter volume and cognitive function across various genetic groups related to FTD.
  • Results indicate that carriers of the minor allele of rs1990622 show increased gray matter volume and better cognitive performance, especially in the thalamus and among presymptomatic individuals.
View Article and Find Full Text PDF

Severe mental illnesses (SMI), especially schizophrenia and bipolar disorder (BD), are associated with significant distress to patients, reduced life expectancy and a higher cost of care. There is growing evidence that SMI may increase the risk of dementia in later life, posing an additional challenge in the management of these patients. SMI present a complex and highly heterogeneous pathophysiology, which has hampered the understanding of its underlying pathological mechanisms and limited the success of the available therapies.

View Article and Find Full Text PDF

Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.

Neurology

October 2024

From the Department of Psychiatry and Neurosciences (X.W., S.D.F., L.-S.S., L.P., O.P.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Experimental and Clinical Research Center (ECRC) (X.W., S.D.F., L.-S.S., L.P., O.P.); German Center for Neurodegenerative Diseases (DZNE) (S.D.F., J.P., E.J.S., S.A., O.P.); Department of Psychiatry and Psychotherapy (J.P., E.J.S., S.A.), Charité, Berlin; Department of Psychiatry and Psychotherapy (J.P.), School of Medicine, Technical University of Munich, Germany; University of Edinburgh and UK DRI (J.P.), United Kingdom; German Center for Neurodegenerative Diseases (DZNE) (A. Schneider, K.F., F.J., A. Spottke, N.R.-K., F.B., M.W., S.W., A. Ramirez, L.K., M.S.), Bonn; Department of Neurodegenerative Disease and Geriatric Psychiatry (A. Schneider, K.F., M.W., S.W., A. Ramirez, L.K., M.S.), University of Bonn Medical Center; German Center for Neurodegenerative Diseases (DZNE) (J.W.), Goettingen; Department of Psychiatry and Psychotherapy (J.W., N.H.), University Medical Center Goettingen, University of Goettingen, Germany; Neurosciences and Signaling Group (J.W.), Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Portugal; Department of Psychiatry (F.J., A. Rostamzadeh), Medical Faculty, University of Cologne; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) (F.J., A. Ramirez), University of Cologne, Köln; German Center for Neurodegenerative Diseases (DZNE) (E.D., W.G., E.I.I.), Magdeburg; Institute of Cognitive Neurology and Dementia Research (IKND) (E.D., E.I.I.), Otto-von-Guericke University, Magdeburg; Department for Psychiatry and Psychotherapy (E.I.I.), University Clinic Magdeburg; German Center for Neurodegenerative Diseases (DZNE) (K.B., M.E., R.P.), Munich; Institute for Stroke and Dementia Research (ISD) (K.B., D.J., M.E.), and Department of Psychiatry and Psychotherapy (R.P., B.-S.R.), University Hospital, LMU Munich; Munich Cluster for Systems Neurology (SyNergy) (R.P.), Germany; Ageing Epidemiology Research Unit (AGE) (R.P.), School of Public Health, Imperial College London; Sheffield Institute for Translational Neuroscience (SITraN) (B.-S.R.), University of Sheffield, United Kingdom; Department of Neuroradiology (B.-S.R.), University Hospital, LMU Munich; German Center for Neurodegenerative Diseases (DZNE) (S.J.T., I.K., D.G.), Rostock; Department of Psychosomatic Medicine (S.J.T., I.K., D.G.), Rostock University Medical Center; German Center for Neurodegenerative Diseases (DZNE) (C.L., M.H.J.M.), Tübingen; Section for Dementia Research (C.L.), Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy (C.L., M.H.J.M.), University of Tübingen; Department of Neurology (A. Spottke), University of Bonn, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (M.T.H.), University of Luxembourg, Belvaux; Division of Neurogenetics and Molecular Psychiatry (A. Ramirez), Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; and Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (A. Ramirez), San Antonio, TX.

Article Synopsis
  • The study investigates the potential of cerebrospinal fluid (CSF) biomarkers, particularly neurogranin and BACE1, to predict cognitive decline in individuals with subjective cognitive decline (SCD) before developing Alzheimer's disease (AD).
  • Researchers analyzed data from 530 participants and found that higher levels of neurogranin and its ratio to BACE1 were linked to faster cognitive decline and increased risk of progressing from SCD to mild cognitive impairment (MCI).
  • The findings suggest that monitoring neurogranin levels could help in identifying those at greater risk for cognitive decline, potentially aiding in earlier diagnosis and intervention for Alzheimer's disease.
View Article and Find Full Text PDF

Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic.

EBioMedicine

October 2024

Research Center and Memory Clinic, Ace Alzheimer Center Barcelona, Barcelona, Spain; Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA.

Background: The identification of patients with an elevated risk of developing Alzheimer's disease (AD) dementia and eligible for the disease-modifying treatments (DMTs) in the earliest stages is one of the greatest challenges in the clinical practice. Plasma biomarkers has the potential to predict these issues, but further research is still needed to translate them to clinical practice. Here we evaluated the clinical applicability of plasma pTau181 as a predictive marker of AD pathology in a large real-world cohort of a memory clinic.

View Article and Find Full Text PDF

Introduction: Brain magnetic resonance imaging (MRI) and inflammatory biomarkers are crucial for investigating preclinical neurocognitive disorders. Current investigations focus on a few inflammatory markers. The study aims to investigate the associations between inflammatory biomarkers and MRI measures and to examine sex differences among the associations in the Framingham Heart Study.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease.

Methods: We performed a meta-analysis of GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n=2,076).

View Article and Find Full Text PDF

Absence of TNFR1 promotes a protective response in the early phase of hepatic encephalopathy induced by thioacetamide in mice.

Neurosci Lett

November 2024

Departamento de Patologia Geral, Instituto de Ciências Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address:

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome with a wide spectrum of cognitive deficits, motor impairment, and psychiatric disturbances resulting from liver damage. The cytokine TNF has been considered the main cytokine in the development and progression of HE, with a pivotal role in the initiation and amplification of the inflammatory cascade. The aim of the present study was to evaluate the involvement of TNF type 1 receptor (TNFR1) in locomotor deficits and in the levels of TNF, IFN-γ, IL-6, IL-10, IL-12p70, CCL2, CX3CL1 and BDNF from the frontal cortex and hippocampus of TNFR1 knockout mice (TNFR1) mice with HE induced by thioacetamide.

View Article and Find Full Text PDF

Prognostic value of Alzheimer's disease plasma biomarkers in the oldest-old: a prospective primary care-based study.

Lancet Reg Health Eur

October 2024

Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Background: Blood-based biomarkers offer a promising, less invasive, and more cost-effective alternative for Alzheimer's disease screening compared to cerebrospinal fluid or imaging biomarkers. However, they have been extensively studied only in memory clinic-based cohorts. We aimed to validate them in a more heterogeneous, older patient population from primary care.

View Article and Find Full Text PDF
Article Synopsis
  • Neurofilament light chain (NfL) levels serve as a key biomarker for neuro-axonal damage in neurodegenerative disorders, and understanding the genetics behind these levels can reveal important molecular mechanisms.
  • A meta-analysis of genome-wide association studies identified significant genetic loci associated with blood NfL levels in both European and African American populations, highlighting two key regions.
  • The study also indicated that a higher polygenic risk score for NfL correlates with increased levels of other neurodegenerative biomarkers and suggests lower kidney function may lead to elevated NfL levels in the blood.
View Article and Find Full Text PDF

Association analysis of mitochondrial DNA heteroplasmic variants: Methods and application.

Mitochondrion

November 2024

Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA; Framingham Heart Study, NHLBI/NIH, Framingham, MA 01702, USA. Electronic address:

We rigorously assessed a comprehensive association testing framework for heteroplasmy, employing both simulated and real-world data. This framework employed a variant allele fraction (VAF) threshold and harnessed multiple gene-based tests for robust identification and association testing of heteroplasmy. Our simulation studies demonstrated that gene-based tests maintained an appropriate type I error rate at α = 0.

View Article and Find Full Text PDF